I found it interesting that the first reference to brilacidin included “(PMX-30063)”. I think this was a smart move to remind the conference of the past research that PolyMedix was doing with the DoD. You can find out more about that here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164656331
Other than that, it looks like a rehash of what’s already known and that I find to be disappointing. IPIX will likely issue a press release with the slide deck for the presentation and I hope there’s something new there.
BTW: I think the "PhD" designation for Weston and Harness are typos.